Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma

Paul G. Rubinstein, Page C. Moore, Michelle A. Rudek, David H. Henry, Juan C. Ramos, Lee Ratner, Erin Reid, Elad Sharon, Ariela Noy

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences